• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Plasma lipoprotein(a) levels in patients with slow coronary flow.冠状动脉血流缓慢患者的血浆脂蛋白(a)水平
Postepy Kardiol Interwencyjnej. 2013;9(4):323-7. doi: 10.5114/pwki.2013.38404. Epub 2013 Nov 18.
2
Interaction of plasma homocysteine and thyroid hormone concentrations in the pathogenesis of the slow coronary flow phenomenon.血浆同型半胱氨酸与甲状腺激素浓度在冠状动脉血流缓慢现象发病机制中的相互作用。
Cardiology. 2007;108(3):186-92. doi: 10.1159/000096687. Epub 2006 Nov 3.
3
Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.血浆脂蛋白相关磷脂酶 A2 水平升高与冠状动脉慢血流相关。
BMC Cardiovasc Disord. 2020 May 27;20(1):248. doi: 10.1186/s12872-020-01463-8.
4
Increased neopterin levels and its association with angiographic variables in patients with slow coronary flow: an observational study.冠状动脉血流缓慢患者新蝶呤水平升高及其与血管造影变量的关联：一项观察性研究。
Anadolu Kardiyol Derg. 2011 Dec;11(8):692-7. doi: 10.5152/akd.2011.190. Epub 2011 Nov 16.
5
Assessment of risk factors and left ventricular function in patients with slow coronary flow.冠状动脉血流缓慢患者的危险因素及左心室功能评估
Heart Vessels. 2016 Mar;31(3):288-97. doi: 10.1007/s00380-014-0606-4. Epub 2014 Dec 5.
6
Decreased plasma concentrations of adiponectin in patients with slow coronary flow.冠状动脉血流缓慢患者血浆脂联素浓度降低。
Heart Vessels. 2009 Jan;24(1):1-7. doi: 10.1007/s00380-008-1074-5. Epub 2009 Jan 23.
7
The effects of endothelial dysfunction and inflammation on slow coronary flow.内皮功能障碍和炎症对冠状动脉血流缓慢的影响。
Turk Kardiyol Dern Ars. 2010 Jul;38(5):327-33.
8
Lack of correlation between coronary blood flow and carotid intima media thickness.冠状动脉血流与颈动脉内膜中层厚度之间缺乏相关性。
Clin Hemorheol Microcirc. 2014;56(4):371-81. doi: 10.3233/CH-141808.
9
The relationship between eosinophilia and slow coronary flow.嗜酸性粒细胞增多与冠状动脉血流缓慢之间的关系。
Ther Clin Risk Manag. 2015 Aug 12;11:1187-91. doi: 10.2147/TCRM.S87761. eCollection 2015.
10
Clinical and coronary angiographic characteristics of patients with coronary slow flow.冠状动脉慢血流患者的临床及冠状动脉造影特征
Acta Cardiol. 2008 Oct;63(5):579-84. doi: 10.2143/AC.63.5.2033224.

本文引用的文献

1
Aspirin as a promising drug for slow coronary flow.阿司匹林作为一种治疗冠状动脉血流缓慢的有前景的药物。
Med Hypotheses. 2012 Nov;79(5):701-2. doi: 10.1016/j.mehy.2012.07.022. Epub 2012 Aug 24.
2
Optimal therapy for reduction of lipoprotein(a).脂蛋白(a)降低的最佳治疗方法。
J Clin Pharm Ther. 2012 Feb;37(1):1-3. doi: 10.1111/j.1365-2710.2011.01244.x. Epub 2011 Jan 30.
3
Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.脂蛋白(a)水平与黑人和白人受试者心血管结局的关系：动脉粥样硬化风险社区（ARIC）研究。
Circulation. 2012 Jan 17;125(2):241-9. doi: 10.1161/CIRCULATIONAHA.111.045120. Epub 2011 Nov 29.
4
Vascular endothelial function in patients with coronary slow flow and the effects of nebivolol.冠状动脉慢血流患者的血管内皮功能及奈必洛尔的作用。
Arq Bras Cardiol. 2011 Oct;97(4):275-80. doi: 10.1590/s0066-782x2011005000105. Epub 2011 Oct 21.
5
Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.脂蛋白（a）与心血管疾病风险——前瞻性研究的系统评价与荟萃分析
Clin Lab. 2011;57(3-4):143-56.
6
Serum lipoprotein (a) levels in patients with arterial hypertension.动脉高血压患者的血清脂蛋白（a）水平
Rev Med Chir Soc Med Nat Iasi. 2010 Jul-Sep;114(3):798-802.
7
Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study.传统和孟德尔随机化分析表明脂蛋白(a)与早期动脉粥样硬化之间没有关联：年轻芬兰人研究。
Int J Epidemiol. 2011 Apr;40(2):470-8. doi: 10.1093/ije/dyq205. Epub 2010 Nov 14.
8
Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control.2型糖尿病中的脂蛋白(a)：与低密度脂蛋白：高密度脂蛋白比值及血糖控制的关系。
Int J Diabetes Dev Ctries. 2009 Apr;29(2):80-4. doi: 10.4103/0973-3930.53125.
9
Lipoprotein(a) and ischemic heart disease--a causal association? A review.脂蛋白(a)与缺血性心脏病——因果关联？一篇综述。
Atherosclerosis. 2010 Jul;211(1):15-23. doi: 10.1016/j.atherosclerosis.2009.12.036. Epub 2010 Jan 11.
10
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.脂蛋白(a)浓度与冠心病、中风及非血管性死亡风险
JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063.

冠状动脉血流缓慢患者的血浆脂蛋白(a)水平

Plasma lipoprotein(a) levels in patients with slow coronary flow.

作者信息

Yucel Habil, Dogan Abdullah, Altinbas Ahmet, Akcay Salaheddin, Icli Atilla, Ceyhan Betul Mermi

机构信息

Department of Cardiology, State Hospital, Isparta, Turkey.

Department of Cardiology, Suleyman Demirel University, Medical School, Isparta, Turkey.

出版信息

Postepy Kardiol Interwencyjnej. 2013;9(4):323-7. doi: 10.5114/pwki.2013.38404. Epub 2013 Nov 18.

DOI:10.5114/pwki.2013.38404
PMID:24570746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3927102/
Abstract

INTRODUCTION

Slow coronary flow (SCF) is a microvascular disorder characterized by delayed opacification of coronary vessels with normal coronary angiogram. It may be due to endothelial dysfunction and diffuse atherosclerosis. Lipoprotein(a) [Lp(a)] is related to cardiovascular events. Plasma Lp(a) levels have not been studied previously in SCF patients.

AIM

We investigated plasma Lp(a) and fibrinogen levels, and their relation to coronary flow rate in patients with SCF.

MATERIAL AND METHODS

This cross-sectional study included 50 patients with SCF and 30 age- and sex-matched controls who had normal coronary arteries and normal flow. Coronary flow rates of patients and controls were counted with the thrombolysis in myocardial infarction (TIMI) frame count. Plasma Lp(a) and fibrinogen levels were measured in SCF patients and controls, with routine biochemical tests.

RESULTS

There were no significant differences between the two groups with respect to plasma Lp(a) (21 mg/dl vs. 14 mg/dl, p = 0.11) and fibrinogen (278 mg/dl vs. 291 mg/dl, p = 0.48) levels. The TIMI frame count was not correlated with plasma Lp(a) (r = 0.13, p = 0.25) or fibrinogen (r = -0.14, p = 0.28) levels.

CONCLUSIONS

Our results show that there is no significant association between SCF and Lp(a) and fibrinogen levels.

摘要

引言

冠状动脉血流缓慢（SCF）是一种微血管疾病，其特征是冠状动脉造影正常但冠状动脉血管造影剂显影延迟。它可能是由于内皮功能障碍和弥漫性动脉粥样硬化所致。脂蛋白（a）[Lp（a）]与心血管事件有关。此前尚未对SCF患者的血浆Lp（a）水平进行研究。

目的

我们研究了SCF患者的血浆Lp（a）和纤维蛋白原水平，以及它们与冠状动脉血流速度的关系。

材料和方法

这项横断面研究纳入了50例SCF患者和30例年龄及性别匹配的对照者，后者冠状动脉正常且血流正常。通过心肌梗死溶栓（TIMI）帧数计算患者和对照者的冠状动脉血流速度。采用常规生化检测方法测量SCF患者和对照者的血浆Lp（a）和纤维蛋白原水平。

结果

两组患者的血浆Lp（a）水平（21mg/dl对14mg/dl，p = 0.11）和纤维蛋白原水平（278mg/dl对291mg/dl，p = 0.48）无显著差异。TIMI帧数与血浆Lp（a）水平（r = 0.13，p = 0.25）或纤维蛋白原水平（r = -0.14，p = 0.28）均无相关性。

结论

我们的结果表明，SCF与Lp（a）及纤维蛋白原水平之间无显著关联。